AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 139 filers reported holding AMICUS THERAPEUTICS INC in Q3 2016. The put-call ratio across all filers is 0.28 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,477,961 | -9.7% | 697,201 | -6.7% | 0.00% | -33.3% |
| Q2 2023 | $9,389,250 | +22.4% | 747,552 | +8.1% | 0.00% | +50.0% |
| Q1 2023 | $7,672,213 | +15.4% | 691,813 | +27.1% | 0.00% | 0.0% |
| Q4 2022 | $6,647,014 | +45.8% | 544,391 | +24.7% | 0.00% | +100.0% |
| Q3 2022 | $4,560,000 | -9.8% | 436,732 | -7.2% | 0.00% | -50.0% |
| Q2 2022 | $5,053,000 | -13.6% | 470,506 | -23.8% | 0.00% | +100.0% |
| Q1 2022 | $5,847,000 | -22.0% | 617,423 | -4.9% | 0.00% | -50.0% |
| Q4 2021 | $7,499,000 | +4.6% | 649,308 | -13.5% | 0.00% | 0.0% |
| Q3 2021 | $7,171,000 | +40.8% | 750,892 | +42.2% | 0.00% | +100.0% |
| Q2 2021 | $5,092,000 | -23.0% | 528,167 | -21.0% | 0.00% | 0.0% |
| Q1 2021 | $6,609,000 | -27.5% | 668,921 | +69.5% | 0.00% | -50.0% |
| Q4 2020 | $9,110,000 | +168.1% | 394,530 | +64.0% | 0.00% | +100.0% |
| Q3 2020 | $3,398,000 | -25.3% | 240,595 | -20.2% | 0.00% | 0.0% |
| Q2 2020 | $4,547,000 | +92.5% | 301,534 | +18.0% | 0.00% | 0.0% |
| Q1 2020 | $2,362,000 | -19.5% | 255,494 | -15.2% | 0.00% | 0.0% |
| Q4 2019 | $2,935,000 | +30.4% | 301,383 | +7.4% | 0.00% | 0.0% |
| Q3 2019 | $2,251,000 | -28.6% | 280,668 | +11.1% | 0.00% | 0.0% |
| Q2 2019 | $3,154,000 | -5.0% | 252,696 | +3.5% | 0.00% | 0.0% |
| Q1 2019 | $3,319,000 | +45.6% | 244,035 | +2.6% | 0.00% | 0.0% |
| Q4 2018 | $2,279,000 | -67.9% | 237,863 | -63.3% | 0.00% | -50.0% |
| Q3 2018 | $7,105,000 | -30.5% | 647,274 | -8.0% | 0.00% | -33.3% |
| Q2 2018 | $10,224,000 | -75.9% | 703,592 | -75.5% | 0.00% | -76.9% |
| Q1 2018 | $42,501,000 | +279.0% | 2,868,852 | +251.2% | 0.01% | +333.3% |
| Q4 2017 | $11,213,000 | +275.9% | 816,905 | +313.0% | 0.00% | +200.0% |
| Q3 2017 | $2,983,000 | +147.6% | 197,804 | +65.3% | 0.00% | – |
| Q2 2017 | $1,205,000 | +10.1% | 119,662 | -22.0% | 0.00% | – |
| Q1 2017 | $1,094,000 | +63.0% | 153,473 | +2.9% | 0.00% | – |
| Q4 2016 | $671,000 | +28.1% | 149,186 | +64.6% | 0.00% | – |
| Q3 2016 | $524,000 | +126.8% | 90,623 | +114.3% | 0.00% | – |
| Q2 2016 | $231,000 | -45.5% | 42,280 | -15.7% | 0.00% | – |
| Q1 2016 | $424,000 | +2.9% | 50,163 | +18.3% | 0.00% | – |
| Q4 2015 | $412,000 | -41.4% | 42,417 | -15.5% | 0.00% | – |
| Q3 2015 | $703,000 | +21.4% | 50,214 | +23.0% | 0.00% | – |
| Q2 2015 | $579,000 | -40.2% | 40,822 | -54.1% | 0.00% | – |
| Q1 2015 | $968,000 | +301.7% | 88,900 | +206.9% | 0.00% | – |
| Q4 2014 | $241,000 | +2577.8% | 28,969 | +655.2% | 0.00% | – |
| Q2 2013 | $9,000 | – | 3,836 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |